Apr 18 |
Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
|
Apr 18 |
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
|
Mar 28 |
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
|
Mar 27 |
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
|
Mar 27 |
Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML
|
Mar 27 |
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
|
Mar 26 |
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
|
Mar 25 |
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
|
Mar 25 |
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
|
Mar 22 |
Earnings Scheduled For March 22, 2024
|